Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737268 | 0.77 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL3787517 | 0.77 | KDM4E (0.35) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL553988 | 0.75 | SMPD3 (0.39) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL16520587 | 0.73 | KDM4E (0.33) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL16520588 | 0.73 | KDM4E (0.33) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL4751320 | 0.73 | — | — | |
| SCHEMBL3695993 | 0.70 | KDM4E (0.32) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL553498 | 0.70 | KDM4E (0.32) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL19542400 | 0.70 | KDM4E (0.32) | KDM4EHSD17B10LMNAALDH1A1HPGD | |
| SCHEMBL7976026 | 0.70 | KDM4E (0.35) | KDM4EHSD17B10LMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090479-A1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
| US-8236832-B2 | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | KDM4E 2191/4885HSD17B10 2252/4885LMNA 4258/4885 |
| US-20130090479-A1 | THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K5, MAP3K1, MAP3K20 | KDM4E 2143/4885HSD17B10 4045/4885LMNA 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.